BCRX vs. NK, TSHA, ADAP, VXRT, ATHA, MDGL, ALKS, FOLD, CLDX, and NVAX
Should you be buying BioCryst Pharmaceuticals stock or one of its competitors? The main competitors of BioCryst Pharmaceuticals include NantKwest (NK), Taysha Gene Therapies (TSHA), Adaptimmune Therapeutics (ADAP), Vaxart (VXRT), Athira Pharma (ATHA), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), and Novavax (NVAX). These companies are all part of the "medical" sector.
BioCryst Pharmaceuticals (NASDAQ:BCRX) and NantKwest (NASDAQ:NK) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, community ranking, risk and analyst recommendations.
BioCryst Pharmaceuticals received 204 more outperform votes than NantKwest when rated by MarketBeat users. Likewise, 66.43% of users gave BioCryst Pharmaceuticals an outperform vote while only 53.32% of users gave NantKwest an outperform vote.
In the previous week, BioCryst Pharmaceuticals had 12 more articles in the media than NantKwest. MarketBeat recorded 12 mentions for BioCryst Pharmaceuticals and 0 mentions for NantKwest. BioCryst Pharmaceuticals' average media sentiment score of 1.19 beat NantKwest's score of 0.00 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.
NantKwest has lower revenue, but higher earnings than BioCryst Pharmaceuticals. NantKwest is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
BioCryst Pharmaceuticals presently has a consensus target price of $14.00, suggesting a potential upside of 116.72%. Given BioCryst Pharmaceuticals' higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than NantKwest.
85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 9.4% of NantKwest shares are held by institutional investors. 4.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 71.7% of NantKwest shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
BioCryst Pharmaceuticals has a net margin of -58.69% compared to NantKwest's net margin of -76,658.58%. BioCryst Pharmaceuticals' return on equity of 0.00% beat NantKwest's return on equity.
BioCryst Pharmaceuticals has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, meaning that its share price is 161% more volatile than the S&P 500.
Summary
BioCryst Pharmaceuticals beats NantKwest on 12 of the 17 factors compared between the two stocks.
Get BioCryst Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCryst Pharmaceuticals Competitors List
Related Companies and Tools
